Brokerages Set Savara Inc (NASDAQ:SVRA) Price Target at $8.83

Savara Inc (NASDAQ:SVRA) has been given an average rating of “Moderate Buy” by the six research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $8.83.

A number of equities research analysts have recently weighed in on SVRA shares. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Savara in a research note on Thursday, December 19th. Wells Fargo & Company started coverage on Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 price target for the company.

Savara Stock Up 3.2 %

SVRA opened at $2.89 on Monday. Savara has a fifty-two week low of $2.26 and a fifty-two week high of $5.34. The business has a 50-day moving average of $2.73 and a 200-day moving average of $3.33. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The company has a market capitalization of $495.98 million, a PE ratio of -6.72 and a beta of 0.60.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SVRA. Vestal Point Capital LP grew its holdings in Savara by 33.2% in the 4th quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock valued at $33,079,000 after buying an additional 2,685,000 shares during the last quarter. Frazier Life Sciences Management L.P. grew its holdings in shares of Savara by 6.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 8,660,379 shares of the company’s stock worth $26,587,000 after purchasing an additional 502,994 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Savara by 22.9% during the 3rd quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock worth $36,566,000 after purchasing an additional 1,608,522 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Savara by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company’s stock worth $25,512,000 after buying an additional 365,959 shares during the period. Finally, Deerfield Management Company L.P. Series C lifted its position in shares of Savara by 23.2% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 7,964,000 shares of the company’s stock worth $24,449,000 after buying an additional 1,498,223 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.